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Introduction: Interleukin-6 (IL-6) is a key player in systemic arthritis, involved in inflammation and joint destruction.
IL-6 signalling has also been revealed in nerve cells. Recently, IL-6 and in particular IL-6 together with its soluble
IL-6 receptor (sIL-6R) were shown to induce a long-lasting robust sensitization of joint nociceptors for mechanical
stimuli which was difficult to reverse, suggesting that IL-6 signalling plays a significant role in the generation and
maintenance of arthritic pain. Here we tested in a preclinical model of arthritis, antigen-induced arthritis (AIA) in
the rat, whether systemic or local neutralization of IL-6/sIL-6R complexes with soluble glycoprotein 130 (sgp130)
alters arthritic pain and how sgp130 influences the inflammatory process in AIA.
Methods: Rats with AIA were either treated with sgp130 or saline intra-peritoneally or intra-articularly (each group
n = 9). Then, pain-related and locomotor behaviour, as well as joint swelling, were measured during an observation
period of 21 days, followed by histopathological end-point analysis for inflammatory and destructive changes.
Results: A single intra-articular application of sgp130 at the time of AIA induction barely reduced the development
of AIA, but significantly attenuated pain-related behaviour, that is, primary mechanical hyperalgesia in the acute
phase of AIA. By contrast, repeated systemic application of sgp130 after onset of AIA only slightly attenuated pain
at a late stage of AIA. None of the treatments reduced secondary hyperalgesia. Furthermore, in the present study
joint destruction at 21 days was significantly attenuated after intra-articular sgp130 treatment, but not after
systemic sgp130.
Conclusions: In addition to its role in chronic inflammation, IL-6 in the joint plays a significant role in the
generation and maintenance of arthritic joint pain at acute and chronic stages of AIA. The particular effectiveness
of intra-articular injection of sgp130 indicates, first, that IL-6/sIL-6R in the inflamed joint, rather than circulating IL-6/
sIL-6R, is responsible for the generation of hyperalgesia, and, second, that early neutralization of IL-6/sIL-6R is
particularly successful in producing antinociception. Furthermore, neutralization of IL-6/sIL-6R (and possibly other
cytokines which use the transmembrane signal-transducing subunit gp130) directly at the site of joint inflammation
seems to be effective in the prevention of joint destruction.
Introduction
The cytokine interleukin-6 (IL-6) is thought to be a key
player in systemic inflammation and arthritis [1], as
shown, for example, by significantly attenuated antigen-
induced arthritis in IL-6-deficient mice [2]. In a murine
model of human tumour necrosis factor- (TNF)
mediated inflammation, IL-6 was found to be particu-
larly involved in inflammation-evoked osteoclast forma-
tion and bone erosion [3]. IL-6 signalling not only
depends on the presence of IL-6 but also on various
cofactors. IL-6 can bind to a membrane-bound IL-6
receptor (IL-6R) which acts in cooperation with the
transmembrane signal-transducing subunit soluble gly-
coprotein 130 (gp130) [4,5]. Alternatively, IL-6 can bind
to a soluble IL-6 receptor (sIL-6R), and the IL-6/sIL-6R
* Correspondence: hans-georg.schaible@mti.uni-jena.de
1Institute of Physiology I/Neurophysiology Jena University Hospital - Friedrich
Schiller University, Teichgraben 8, D-07743 Jena, Germany
Boettger et al. Arthritis Research & Therapy 2010, 12:R140
http://arthritis-research.com/content/12/4/R140
© 2010 Boettger et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.complex can bind to the transmembrane signal-transdu-
cing subunit gp130 of cells which do not express the
membrane-bound IL-6R, thus leading to IL-6 trans-
signalling [5]. In fact, in the serum, synovial fluid and
synovial tissue of rheumatoid arthritis patients the con-
centrations of both IL-6 [6,7] and sIL-6R [8,9] are ele-
vated. While sIL-6R acts as an agonist, circulating
soluble gp130 (sgp130) acts as an antagonist, because it
binds IL-6/sIL-6R complexes and thus prevents trans-
signalling [4,5]. In murine arthritis models, neutraliza-
tion of IL-6 transsignalling by administration of sgp130
was shown to reduce inflammation [2,10-12].
In addition, it has been suggested that IL-6 plays an
important role in the generation of inflammatory pain.
Using electrophysiological recordings from nociceptors
of the rat knee joint, we recently found that the injec-
tion of IL-6 or of IL-6 together with sIL-6R into a nor-
mal knee caused a long-lasting sensitization of
nociceptive C-fibres for mechanical stimuli applied to
the joint [13]. This sensitization is likely to be caused at
least in part by a direct effect on the nerve fibres,
because most peripheral nerve fibres were shown to
express the transmembrane signal-transducing subunit
gp130 [14,15]. The sensitizing effect of IL-6 was pre-
vented by co-administration of sgp130 which binds and
inactivates IL-6/IL-6R complexes [5]. Interestingly, how-
ever, sgp130 did not reduce the enhanced mechanosen-
sitivity when it was administered into the joint one hour
after IL6 or IL-6/sIL-6R [13] suggesting that IL-6 might
induce a state of persistent hyperexcitability which is
difficult to reverse. In line with this, it has been reported
that 24 hours after the injection of IL-6 into skeletal
muscle an additional injection of PGE2 into the muscle
caused stronger nociceptive behaviour than under con-
trol conditions, and it was concluded that IL-6 caused
long-term priming of nociceptive neurones [16].
While the available data suggest that IL-6 (trans)sig-
nalling may be important for pain and inflammation, no
study has investigated how neutralization of IL-6 trans-
signalling affects pain in an arthritis model. Therefore,
in the present study we explored in the rat the effect of
neutralization of IL-6 transsignalling on pain-related
behaviour and inflammation in the unilateral model of
antigen-induced arthritis (AIA). In order to neutralize
IL-6 transsignalling, we used sgp130 which has been
employed in previous studies on inflammation [2,11]
and pain [13]. In the first approach, we repeatedly admi-
nistered sgp130 intra-peritoneally during the course of
AIA, starting six hours after arthritis induction. Employ-
ing such an approach, we previously found that the
TNF-a neutralizing compounds etanercept and inflixi-
mab strongly reduced mechanical hyperalgesia at the
inflamed knee joint and slightly but significantly
decreased swelling at the inflamed joint [17]. In a
second approach, we administered sgp130 into the knee
joint together with the antigen upon arthritis induction.
We analyzed pain-related and locomotor behaviour,
knee swelling and, using histopathology, the severity of
inflammation at the end of the observation period at 21
days after induction of arthritis.
Materials and methods
Antigen-induced arthritis (AIA)
Forty-five female Lewis rats (age six to eight weeks,
weighing 160 to 180 g, Charles River, Sulzfeld, Ger-
many) were used. All experiments were approved by the
Thuringian state authorities and complied with EC regu-
lations (86/609/EEC). AIA was induced as reported pre-
viously [18,19]. In brief, 500 μgm e t h y l a t e db o v i n e
serum albumin (m-BSA; Sigma, Deisenhofen, Germany)
in saline emulsified with 500 μl Freund’sc o m p l e t ea d j u -
vant (Sigma; supplemented with 2 mg/ml Mycobacter-
ium tuberculosis strain H37RA; Difco, Detroit, MI, USA)
were injected sub-cutaneously (s.c.) twice during a one
week interval for immunization. After another two
weeks, m-BSA (500 μgi n5 0μl saline) was injected into
the left knee joint cavity to induce monoarticular AIA.
Treatment protocols
We used recombinant human soluble gp130 (sgp130,
R&D Systems, Minneapolis, MN, USA) which is effec-
tive in different species [2,4,13]. Nine animals received
sgp130 intra-peritoneally (i.p.) (1 μg dissolved in 200 μl
saline starting six hours after induction of AIA and on
every third day until Day 12 after induction). Another
nine rats were treated with sgp130 intra-articularly (i.a.,
100 ng in 50 μl), which was injected simultaneously to
m-BSA application. Data were compared to those from
animals receiving saline i.a. (50 μl injected together with
m-BSA at the time of arthritis induction), saline i.p. at
the same time points as i.p.-sgp130 treatment was per-
formed (0.9% NaCl, volume 200 μl), and to animals that
were immunized, but in which no arthritis was induced
(controls, each n = 9).
Behavioural experiments
Pain-related behaviour
Primary hyperalgesia at the site of the inflamed knee
was assessed using a dynamometer (Correx, Berne, Swit-
zerland) as described previously [19]. In brief, increasing
pressure was applied to the lateral side of the knee joint
at the level of the joint space until the animals
attempted to escape or vocalized. In order to quantify
the antinociceptive effects of sgp130 over time, areas
under the curves (AUC) depicting the changes of
thresholds over time were calculated for both saline-
and both sgp130-treated groups. The areas used for ana-
lyses were the integrals over the time points assessed.
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ferences from the baseline value for each group for two
consecutive time points when testing took place, for
example, Days 1 and 7, multiplied with the number of
days in this interval. The total area was obtained by add-
ing the values from all intervals (1 to 3, 3 to 7, 7 to 14
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In this calculation, an antinociceptive effect of 0%
means a reduction in thresholds to the same extent as
in saline-treated animals, while 100% would indicate a
complete return to baseline values on all testing days.
Pain-related guarding behaviour was assessed by quan-
tification of weight bearing towards the non-inflamed
hindlimb using an incapacitance tester (Linton Intru-
mentation, Norfolk, UK). Animals were placed in a plas-
tic cage with both hindpaws resting on scales. The
weight force on both scales was obtained and averaged
for three seconds and values from three consecutive
measurements were obtained for every testing day.
From these values, the relative weight resting on the
inflamed hindlimb was calculated as described pre-
viously [20].
Secondary hyperalgesia was assessed at sites remote
from the inflamed joint, the paw and the contralateral
knee joint. Mechanical secondary hyperalgesia at the
contralateral knee joint was assessed as described above.
In addition, secondary mechanical hyperalgesia was
obtained from the paw using a dynamic plantar aesthesi-
ometer (Ugo Basile, Comerio, Italy) as previously
described [21]. This device reflects an automated form
of von Frey hair testing with a blunt filament touching
the paw on the plantar surface while the animal rests on
a mesh floor. Then, pressure is increased until the ani-
mal withdraws its limb, and the weight force needed to
elicit this response can be read out in grams. In this
study, 50 g were defined as cut-off and a ramp speed of
2.5 g/s was chosen according to the procedure pre-
viously reported [22]. After allowing the animals to
habituate to the device for 30 minutes, measurements
were taken in triplicate over a period of approximately
half an hour and means were taken as secondary
mechanical hyperalgesic thresholds. Thermal secondary
hyperalgesia at the hindpaws was assessed with an alge-
simeter (Ugo Basile, Comerio, Italy) as described pre-
viously [23,24].
Gait analysis
Paw prints were obtained as described previously (see
[19,25]). From these prints, the distance between a print
from the left (inflamed) paw and a consecutive print
from the right (non-inflamed) paw (left-right-distance),
mainly indicating pain [19], and the angle between con-
secutive paw prints, which has been associated with
joint destruction [19], were assessed. For each animal
and testing day, at least five gait cycles were analysed. In
addition, a guarding score was assessed: 0: no guarding,
1: guarding of the hindlimb after a defined brief noxious
compression of the knee, 2: visible limping during walk-
ing without previous pain stimulus, 3: no use of the hin-
dlimb with the arthritic knee.
Joint swelling
Swelling was assessed by measuring the mediolateral
diameter of each knee using a vernier caliper (Mitutoyo,
Neuss, Germany). For each animal and testing day, swel-
ling was calculated by subtracting the diameter of the
non-inflamed from the inflamed knee. In analogy to the
antinociceptive effect described above, an anti-inflamma-
tory effect was calculated, again taking into account the
time course of swelling in the respective saline-treated
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Histopathological grading of joint inflammation and
destruction
Histology of the knee joints was assessed on Day 21
after AIA induction as described previously [17,19].
Under deep anesthesia with sodium thiopentone rats
were perfused with PBS and 4.0% phosphate-buffered
formalin. Knee joints were removed, skinned, post-fixed
in formalin, decalcified in 7% AlCl3, embedded in paraf-
fin, cut into 5 μm thick frontal sections and stained
with hematoxylin-eosin. Two independent observers
(MG, RB) unaware of the treatment scored the sections
for cellular infiltration and hyperplasia (0: no, 1: mild, 2:
moderate, 3: severe alterations), cartilage destruction
and bone erosion (0: no erosion, 1: erosion of < 10%, 2:
of 10 to 25%, 3: of 25 to 50%, and 4: of > 50% of carti-
lage and bone).
Statistical Analyses
For statistical analyses, SPSS for Windows was used
(version 17.0). Data were tested for normal distribution
applying Kolmogorov-Smirnov-test. Behavioural data
were compared between groups using repeated measures
ANOVAs with the between-subjects factor treatment
(sgp130 i.a., sgp130 i.p., saline i.a., saline i.p.) and the
within-subjects factor time (baseline, Days 1, 3, 7, 14
and 21 after induction of arthritis for all parameters
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distances and angles between paws, for which baseline
and Days 7, 14 and 21 were included). Differences
between treatment groups (sgp130 i.a. versus sgp130
i.p.; sgp130 i.a. versus saline i.a.; sgp130 i.p. versus saline
i.p.) were analyzed for each testing day applying post-
hoc t-tests.
For comparison of histological scores between groups,
one-way ANOVAs were employed, followed by post-hoc
t-tests. Antinociceptive and anti-inflammatory effects
were compared between i.a.- and i.p.-sgp130-treated ani-
mals using unpaired two-sided t-tests. Significance was
assumed for P < 0.05.
Results
In the text, results from statistical analyses are displayed
as values from multivariate testing, while figures and
tables show results from post-hoc t-tests.
Behavioural assessment
Pain-related behaviour
Primary mechanical hyperalgesia as assessed by
mechanical threshold testing at the inflamed knee joint
showed a significant time × treatment interaction (F
(15,78) = 3.743; P < 0.001). In particular, while saline-
treated animals showed severe hyperalgesia indicated
by a large reduction of mechanical pain thresholds,
nociceptive thresholds were significantly increased in
the i.a.-treated group on Days 3 and 7 (Figure 1a), but
not in the i.p.-treated group, in which an increase in
thresholds was obvious, however, in the chronic phase
of AIA, that is, on Days 14 and 21 (Figure 1b).
Differences between i.a.- and i.p.-sgp130-treated ani-
mals were significant on Days 3 and 7 (P < 0.001). The
calculation of areas under the curve revealed a signifi-
cantly greater overall antinociceptive effect in the i.a.-
treated animals as compared to the i.p.-treated animals
(P = 0.014; Figure 1c).
Weight bearing as a functional measure for pain-
related behaviour showed a significant time × treatment
interaction (F(15,78) = 1.900; P = 0.036). Here, i.a. treat-
ment attenuated the decrease in weight resting on the
inflamed hindpaw in the acute phase and accelerated
the normalization of this parameter (Table 1), which
was also superior to systemic treatment.
By contrast, measures of secondary hyperalgesia
assessed at the paw revealed no significant time × treat-
ment interaction for mechanical thresholds (F(15,78) =
1.333; P = 0.218, see Table 1) or for thermal withdrawal
thresholds (F(15,78) = 1.328; P = 0.206, see Table 1).
Locomotor behaviour
Assessment of gait revealed no gross difference in
guarding behaviour as assessed using the limping score
(F(15,78) = 1.274; P = 0.239). However, objective gait
analysis as displayed in Figure 2c (no inflammation) and
2f (i.a.-saline- and i.a.-sgp130-treated AIA animals)
showed a significant time × treatment interaction for
left-right-distance (F(9,71) = 3.812; P < 0.001), which
has been suggested to also mainly indicate pain [19].
Here, distances were normalizing from Day 14 in the
i.a.-sgp130-treated group, but not in the saline- and i.p.-
treated groups (Figure 2a, b). A significant difference
between sgp130-i.a. and sgp130-i.p. treatment was
obvious on Day 14 only (P = 0.026).
Figure 1 Pain-related behaviour in the different treatment groups. (a) Thresholds indicating primary mechanical hyperalgesia are
significantly reduced in saline i.a.-treated animals in the acute phase of arthritis, i.a.-sgp130-treated animals show a significantly faster recovery
with increased thresholds on Days 3 and 7 after induction of arthritis. (b) i.p.-sgp130-treated animals show a faster increase of thresholds as
compared to i.p.-saline-treated animals in the chronic phase of AIA (Days 14 and 21). (c) Overall antinociceptive effects as calculated from areas
under the curve. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; n = 9 for all groups. Controls in (A) and (B) show values from
immunized rats without AIA induction.
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destruction [19] were significantly different between
groups (F(9,71) = 2.047; P = 0.046). Again, i.a. treatment
with sgp130 attenuated the inflammation-related gait
changes (Figure 2d, f), while i.p.-sgp130 application was
not different from i.p.-saline treatment (Figure 2e). On
Days 14 and 21, significant differences could further be
obtained between sgp130-i.a.- and sgp130-i.p.-treatment
(P = 0.012 and P = 0.022, respectively).
For all objective gait parameters, only Days 7 to 21
were analyzed, since only few AIA animals utilized their
inflamed hindlimb in the acute phase on days 1 and 3
( s a l i n ei . a .n=3 ;s a l i n ei . p .n=3 ;s g p 1 3 0i . a .n=6 ;
sgp130 i.p. n = 4).
Measurement of inflammation
Joint swelling differed significantly in regard to treat-
ment (F(15,78) = 2.166; P =0 . 0 1 5 )w i t hl o w e s tv a l u e s
being apparent in the i.a.-sgp130-treated group (Figure
3a), and rather a slight aggravation in the i.p.-treated
animals (Figure 3b). Differences between i.p.- and i.a.-
sgp130 treatment were significant on Days 3, 7, and 21
(P = 0.030, 0.011, and 0.011, respectively). Overall, the
effects of either i.a.- and i.p-sgp130 treatment on joint
swelling were not very pronounced, even in the i.a.-trea-
ted group, resulting in small differences in the anti-
inflammatory effects as obtained from area under the
curve analyses, which did not show statistical signifi-
cance (P = 0.168; Figure 3c). Histopathological scores
for inflammation at day 21 of AIA did not significantly
differ between treatment groups (F = 0.174; P = 0.913;
Figure 3d). However, scores for cartilage and bone
destruction showed an effect, with least destruction in
the i.a.-sgp130-treated group (F = 3.462; P = 0.028;
Figure 3e).
Discussion
In this study, we show that a single injection of sgp130
i n t ot h ek n e ej o i n ta tt h et i m eo fa r t h r i t i si n d u c t i o n
caused a significant long-term antinociceptive effect,
although acute arthritis per se was barely attenuated.
Antinociception is expressed as an increase of mechani-
cal thresholds at the knee joint (reduction of hyperalge-
sia) and a faster normalization of pain-related gait
disturbances. By contrast, repeated i.p. injection of
sgp130 in the course of AIA reduced mechanical hyper-
algesia only weakly, at a time point where AIA is already
in the process of remission. Swelling was only weakly
reduced by sgp130, but the effect of i.a. sgp130 was sig-
nificantly greater than the effect of i.p. sgp130 on Day 7
of AIA. Histopathological scoring of inflammation did
n o ts h o wa ne f f e c to fs g p 1 3 0u p o ne i t h e ri . a .o ri . p
application but i.a. sgp130 produced a significant reduc-
tion of the score of cartilage and bone destruction.
The previous electrophysiological recordings from
joint afferents revealed that injection of IL-6, and in par-
ticular injection of IL-6 together with its soluble recep-
tor into the normal joint induces long-lasting
sensitization for mechanical stimuli [13]. The significant
antinociceptive effect of the intra-articular injection of
sgp130 in the present study suggests that endogenous
IL-6/sIL-6R indeed plays a significant role in the genera-
tion of arthritic joint pain. As a caveat it should be
noted that sgp130 is not only restricted to sIL-6R signal-
ling, as sgp130 also regulates the IL-6-related cytokines
leukemia inhibiting factor (LIF) and oncostatin M
Table 1 Measures of secondary hyperalgesia and weight bearing
Treatment Baseline Day 1 Day 3 Day 7 Day 14 Day 21
Weight bearing [% on inflamed hindlimb]
Saline i.p. 49.7 ± 0.7 23.5 ± 3.1 27.0 ± 1.1 31.6 ± 2.4 40.0 ± 2.6 50.3 ± 2.1
Sgp130 i.p. 49.8 ± 0.6 27.0 ± 2.6 25.3 ± 2.5 26.1 ± 3.3 40.8 ± 2.5 46.4 ± 1.7
Saline i.a. 51.1 ± 0.6 30.6 ± 3.8 30.3 ± 1.5 33.6 ± 2.8 39.2 ± 2.4 45.5 ± 1.0
Sgp130 i.a. 50.6 ± 0.8 32.4 ± 0.8 * 38.0 ± 1.7
+,** 43.2 ± 1.3
+,** 44.2 ± 1.2 48.4 ± 2.5
Mechanical thresholds paw [g]
Saline i.p. 26.2 ± 2.9 16.6 ± 1.7 12.5 ± 1.5 12.2 ± 1.3 12.3 ± 1.0 14.6 ± 1.9
Sgp130 i.p. 24.6 ± 3.0 14.2 ± 2.4 16.7 ± 1.9 14.0 ± 1.1 12.3 ± 1.8 13.3 ± 1.7
Saline i.a. 22.9 ± 2.1 14.5 ± 3.7 12.8 ± 1.8 9.8 ± 2.6 9.0 ± 2.4 12.3 ± 2.4
sgp130 i.a. 24.4 ± 1.6 15.5 ± 2.0 14.5 ± 2.2 12.7 ± 1.8 15.1 ± 2.6 14.7 ± 2.1
Thermal withdrawal thresholds paw [s]
Saline i.p. 15.3 ± 0.8 10.3 ± 0.9 10.3 ± 0.9 8.7 ± 0.8 8.4 ± 0.9 9.3 ± 0.9
sgp130 i.p. 14.9 ± 0.7 10.2 ± 0.8 11.3 ± 1.4 8.2 ± 1.3 9.4 ± 1.0 10.2 ± 0.9
Saline i.a. 14.9 ± 0.6 9.8 ± 0.8 9.5 ± 0.8 9.3 ± 1.1 10.1 ± 0.9 10.3 ± 1.3
sgp130 i.a. 13.4 ± 0.7 9.4 ± 0.7 10.7 ± 0.8 10.0 ± 0.7 10.5 ± 1.2 12.4 ± 1.0
Sgp, soluble glycoprotein 130; i.a., intra-articular; i.p., intra-peritoneal; data are presented as mean ± SEM. * differences between sgp130 i.p. and and sgp130 i.a.;
+ differences between sgp130 i.a. and saline i.a.; one symbol P < 0.05; two symbols P <0 . 0 1 .
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and OSM than for the IL-6/sIL-6R complex [5]. While
in mice a prominent role of IL-6 in the AIA model has
been established [2,26,27], the putative role of LIF and
OSM in AIA is unknown. Furthermore, sgp130 is
thought to prevent mainly transsignalling by IL-6/sIL-6R
complexes and not to inhibit the classical IL-6 pathway
[5]. Therefore, the magnitude of effects of IL-6 neutrali-
zation may be underestimated in the present study.
Both the long-lasting antinociceptive effect upon a sin-
gle intra-articular injection at the time of arthritis induc-
tion and the very weak and only late effect of systemic
sgp130 are remarkable. The greater effectiveness of i.a.
sgp130 indicates that IL-6/sIL-6R in the joint is more
important than circulating IL-6/sIL-6R. Although the
dose ratio between i.a.- and i.p.-applied sgp130 was per-
formed according to the same criteria as for etanercept
in previous studies, where systemic application showed
a beneficial effect [17], we cannot completely exclude
that the i.p. sgp130 was underdosed and produced for
this reason a less pronounced, yet detectable effect. It
was pointed out that sgp130 may be present as an endo-
genous antagonist in the circulation and that “am o l a r
excess of sgp130” leads to competitive inhibition of the
IL-6/sIL-6R response [5]. However, not only the site of
intervention (i.a. versus i.p.) may be crucial but also the
timing of injection of sgp130. While the intra-articular
injection of sgp130 was performed simultaneously with
the injection of the antigen into the knee joint and can
therefore be considered as pre-treatment, systemic
Figure 2 Locomotor behaviour in the different treatment groups as assessed from paw print analysis. (a) Left-right (LR) distances in i.a.-
treated animals (for explanation of the parameter, see (c)), showing an attenuation of pain-related gait changes. (b) Left-right distances in i.p.-
treated animals, showing no differences between groups. (d), (e) Angles between paws (for explanation, see (c)) in i.a.- (d) and i.p.- (e) treated
animals, again showing a beneficial effect of i.a. sgp130 treatment. (c), (f) Representative specimens of paw prints from a non-inflamed (c) and a
saline- or sgp130 i.a.-treated animal, respectively (f). Arrows at the right side indicate the direction of walking, LR Left-right distance, RL Right-left
distance. Data in A, B, D and E are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; n = 9 for all groups. Controls in (a), (b), (d), and
(e) show values from immunized rats without AIA induction.
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after induction of inflammation, that is, as post-treat-
ment (same treatment regime as for etanercept and
infliximab). These findings should be seen in the context
of the effect of sgp130 on the IL-6-induced hyperexcit-
ability. The intra-articular injection of sgp130 prevented
the IL-6- or the IL-6/sIL-6R-induced sensitization upon
pre-treatment but sgp130 did not reverse the IL-6- or
IL-6/sIL-6R-induced hyperexcitability when it was
applied after the establishment of hyperexcitability.
These data suggest, therefore, that IL-6 generates a type
of hyperexcitability, which is long-lasting and difficult to
reverse (see Introduction).
We observed some reduction of swelling after i.a.
sgp130 which may correspond to effects in previous stu-
dies in mice which showed a pronounced effect for inhi-
bition of IL-6-transsignalling by sgp130 or splice
variants thereof when applied once intra-articularly
together with the antigen at the time of AIA induction
[2,11]. However, histopathological scoring did not reveal
a significant reduction of the inflammatory process by
Day 21. By contrast, the destruction was significantly
reduced which is in line with a recent study in a murine
model of human TNF-mediated inflammation in which
the blockade of IL-6 receptors impaired osteoclast for-
mation and reduced bone loss, while the inflammatory
Figure 3 Inflammatory changes in the different treatment groups. Joint swelling in i.a.- (a) and i.p.- (b) treated AIA animals as compared to
non-inflamed controls. (c) Anti-inflammatory effects as calculated from areas under the curve. Histopathological scores for inflammation (d) and
cartilage and bone destruction (e) at day 21 of AIA, showing a beneficial effect for i.a.-sgp130-treated animals in the latter. Data are presented as
mean ± SEM. *P < 0.05; n = 9 for all groups.
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This effect might even be pronounced in repeated
inflammatory states. In this respect, in mice it was
found that AIA can be rekindled by further injections of
the antigen into the joint, and with each flare-up reac-
tion joint destruction becomes more severe (unpub-
lished observations).
The present and previous data show differences
between the treatment with sgp130 and TNF-a-neutrali-
zation by etanercept and infliximab. First, systemic eta-
nercept and infliximab clearly reduced mechanical
hyperalgesia as well as secondary hyperalgesia at the
paws at the early and late stage of AIA whereas [17,19]
systemic sgp130 had only a late and weak effect. Second,
injection of etanercept into the inflamed knee joint sig-
nificantly reduced responses of nociceptive fibres within
one hour [17], and etanercept also reduces sensitization
of joint afferents by intra-articular TNF-a injection
(unpublished observations) whereas intra-articular injec-
tion of sgp130 reduced the IL-6/sIL-6R-induced
mechanical sensitization only in a pre-treatment
approach [13]. Thus, we believe that the effects of TNF-
a might overall be more reversible than those of IL-6.
This might be due to its manifold putative sites of
action when interfering with the pain system, that is,
locally at the nerve endings [17], at the dorsal root
ganglia [28], or on the spinal level [29].
Conclusions
In addition to its pathogenetic role in chronic inflamma-
tion and bone destruction, IL-6 in the joint plays a sig-
nificant role in the generation and maintenance of
arthritic joint pain at acute and chronic stages of arthri-
tis. The particular effectiveness of the intra-articular
injection of sgp130 indicates that IL-6/sIL-6R (and pos-
sibly other cytokines which use the transmembrane sig-
nal-transducing subunit gp130) in the inflamed joint,
rather than circulating IL-6/sIL-6R, is responsible for
the generation of hyperalgesia. Furthermore, early neu-
tralization of IL-6/sIL-6R is particularly successful in
producing antinociception. The induction of pain by IL-
6 or IL-6/sIL-6R is likely to result directly from an
action at peripheral neurones because most peripheral
nerve fibres were shown to express the transmembrane
signal-transducing subunit gp130 [14,15]. Similar con-
clusions on the importance of the neuronal target were
d r a w ni nas t u d yo nt h er o l eo fI L - 6o nt h eg e n e r a t i o n
of pathophysiological heat hyperexcitability [30]. Con-
cerning the success of systemic treatment, we would
expect that neutralization of IL-6/sIL-6R is less antinoci-
ceptive than the neutralization of TNF-a because sys-
temic sgp130 reduced mechanical hyperalgesia much
less than systemic etanercept or infliximab [17]. Finally,
early neutralization of IL-6/sIL-6R by sgp130 directly at
the site of joint inflammation was much more effective
in the prevention of joint destruction than systemic
sgp130. It may be useful, therefore, to explore clinically
the effect of intra-articular injection of IL-6/sIL-6R-neu-
tralizing compounds.
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